- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00006289
Neurotropin to Treat Chronic Neuropathic Pain
Neurotropin for Acute Dental Pain and for Chronic Neuropathic Pain
This study will examine the effectiveness of the drug neurotropin in treating chronic pain after injury to a limb or a large nerve.
Two groups of patients will participate in this study: patients with complex regional pain syndrome type 1, or CRPS-I (also called reflex sympathetic dystrophy) and patients with complex regional pain syndrome type 2, or CRPS-II. CRPS-I is pain that develops after relatively minor injury to an arm or leg, but lasts much longer and is much more severe than would normally be expected. CRPS-II is pain resulting from injury to a large nerve. Candidates will have a history and physical examination, blood tests, and electrocardiogram. Participants will undergo the following tests and procedures:
Patients with CRPS I and II will receive an individualized regimen of physical therapy and standard treatment to control their pain. In addition, they will receive neurotropin or placebo tablets for 5 weeks, then no trial medicine for at least 1 week, and then the other trial drug for the next 5 weeks. That is, patients who took placebo the first 5 weeks will take neurotropin the second 5 weeks and vice versa. Neither the patients nor the doctors will know who received which drug during the two intervals until the study is over. Patients will complete questionnaires about their pain, quality of life, and ability to perform daily living activities. They will have various tests to measure pain (such as sensitivity to heat and cold, to an electric current, to a mild pin prick, etc.); to provide information about changes in their condition (such as tests of range of motion of joints and limb size); to measure blood circulation and sweating in the arm or leg (such as measurements of blood flow to the limb, skin temperature, and sweat production), and other procedures.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
CRPS patients are referred with a diagnosis of CRPS-I or CRPS-II in one limb only, based on pain (1) that is post-traumatic and spread beyond the region of the injury; (2) has persisted for more than 2 weeks; and (3) is associated with swelling, altered skin color or skin temperature, altered sweating, allodynia or hyperesthesia or limitation of active movement. Atrophic changes in skin, hair loss or nail changes, or disuse atrophy of skeletal muscle may be present.
Both sexes are to be studied.
All ethnic and racial groups can participate.
Patients must be willing to return to NIH for follow-up evaluation under this protocol.
EXCLUSION CRITERIA:
Pregnant and lactating women are excluded.
Based on the oral surgeon's postoperative diagnosis, any extraction which is classified as producing unusual surgical trauma will result in exclusion from the remainder of the study.
Dental subjects will also be excluded if they are not adequately sedated by midazolam alone and require intraoperative administration of an opioid drug such as fentanyl, administration of greater than 14.4 ml of local anesthetic (2% lidocaine with 1:100,000 epinephrine), or postoperative administration of a steroid for possible injury to the inferior alveolar nerve.
Patients referred with CRPS-I or CRPS II who have abnormal screening test results or who have non-traumatic disorders to which pain may be attributed (gout, malignancy, arthritis, etc.) will be excluded.
Any patients who have had ablative procedures for treatment of their neuropathic pain disorder will not be eligible for inclusion in this study.
Patients who have a positive HIV result will be excluded.
Subjects with obviously impaired mental capacity that precludes informed consent and ability to provide adequate self-ratings are to be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Placebo first, then Neurotropin (G-1)
Double blind cross-over study: receive placebo for 5 weeks and then Neurotropin for 5 weeks (after at least 1 week washout period).
Assignment to each group was in random order, selected by the pharmacy with all others blind.
|
4 tabs b.i.d.
Other Names:
4 tabs b.i.d.
Other Names:
|
Active Comparator: Neurotropin first, then Placebo (G-2)
Double blind cross-over study: receive Neurotropin for 5 weeks and then placebo for 5 weeks (after at least 1 week washout period).
Assignment to each group was in random order, selected by the pharmacy with all others blind.
|
4 tabs b.i.d.
Other Names:
4 tabs b.i.d.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analogue Scale (VAS) of Pain Scores After Administration of Test Drugs (Placebo or Neurotropin )
Time Frame: VAS of each patient is measured after each 5-week treatment interval with placebo or Neurotropin.
|
Assessments of pain severity by the patient using a visual analogue scale ranging from 0 to 100 (mm), with 0 = no pain and 100 = maximal pain level.
When it is difficult to recruit the patients, the interim analysis using these data is performed after completion of the study of first 16 patients (target number is 30).
The data from 16 patients was analyzed while investigators were blinded to the treatment code (Drug A and B) provided by the NIH pharmacy.
Only after the analysis was completed was the code unblinded.
Placebo or Neurotropin" in place of "drug A or drug B.
|
VAS of each patient is measured after each 5-week treatment interval with placebo or Neurotropin.
|
Numeric Rating Scale (NRS) of Pain Scores After Administration of Test Drugs (Neurotropin or Placebo)
Time Frame: NRS of each patient is measured after each five-week treatment interval with placebo or Neurotropin.
|
Assessments of pain severity by the patient using a numeric rating scale ranging from 0 to 10 as a verbal response where 0 = no pain and 10 =maximal pain.
When it is difficult to recruit the patients, the interim analysis using these data is performed after completion of the study of first 16 patients (target number is 30).
The data from 16 patients was analyzed while the investigators are blinded to the treatment code (Drug A or B) provided by the NIH pharmacy.
Only after the analysis was completed was the code unblinded.
Placebo or Neurotropin" in place of "drug A or drug B.
|
NRS of each patient is measured after each five-week treatment interval with placebo or Neurotropin.
|
McGill Pain Questionnaire (MPQ) of Scores After Administration of Test Drugs (Neurotropin or Placebo)
Time Frame: MPQ of each patient is measured after each five-week treatment interval with drug A or drug B.
|
Assessments of pain severity by the patient using a McGill Pain Questionnaire which consists of 3 major classes of word descriptors-sensory, affective and evaluative - that are used by patients to specify subjective pain experience.
Each word chosen from descriptor responses to 20 questions is given a value and the sum of the values of the responses provides a score which is an index of the pain severity with a minimum value of 20 and a maximal value of 78.
When it is difficult to recruit the patients, the interim analysis using these data is performed after completion of the study of first 16 patients (target number is 30).
The data from 16 patients was analyzed while investigators are blinded to the treatment code (drug A or B) provided by the NIH pharmacy.
Only after the analysis was completed was the code unblinded.
Placebo or Neurotropin" in place of "drug A or drug B.
|
MPQ of each patient is measured after each five-week treatment interval with drug A or drug B.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Leorey Saligan, PhD, CRNP, National Institute of Nursing Research (NINR)
Publications and helpful links
General Publications
- Stanton-Hicks M, Janig W, Hassenbusch S, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. 1995 Oct;63(1):127-133. doi: 10.1016/0304-3959(95)00110-E.
- Galer BS, Bruehl S, Harden RN. IASP diagnostic criteria for complex regional pain syndrome: a preliminary empirical validation study. International Association for the Study of Pain. Clin J Pain. 1998 Mar;14(1):48-54. doi: 10.1097/00002508-199803000-00007.
- Bruehl S, Harden RN, Galer BS, Saltz S, Bertram M, Backonja M, Gayles R, Rudin N, Bhugra MK, Stanton-Hicks M. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain. 1999 May;81(1-2):147-54. doi: 10.1016/s0304-3959(99)00011-1.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Disease
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Autonomic Nervous System Diseases
- Syndrome
- Neuralgia
- Complex Regional Pain Syndromes
- Reflex Sympathetic Dystrophy
- Somatoform Disorders
- Causalgia
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Immunologic Factors
- Adjuvants, Immunologic
- Anticonvulsants
- Neurotropin
Other Study ID Numbers
- 000200
- 00-NR-0200 (Other Identifier: NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Complex Regional Pain Syndrome Type I
-
Ruhr University of BochumUnknownComplex Regional Pain Syndrome Type I of the Upper LimbGermany
-
University of ZurichBalgrist University HospitalRecruitingComplex Regional Pain Syndrome I (CRPS I) | Complex Regional Pain Syndromes | Osteoarthritis Hand | Complex Regional Pain Syndrome Type II | Complex Regional Pain Syndrome Type I of the Upper Limb | Complex Regional Pain Syndrome I of Upper Limb | Complex Regional Pain Syndrome II of Upper Limb | Peripheral Nerve Injury Upper Limb and other conditionsSwitzerland
-
University of GroningenWithdrawnComplex Regional Pain Syndrome Type I of the Upper LimbNetherlands
-
University of Sao PauloUniversity of Sao Paulo General HospitalUnknownComplex Regional Pain Syndrome I of Upper LimbBrazil
-
Grünenthal GmbHCompletedComplex Regional Pain Syndrome, Type IUnited States, Germany, United Kingdom
-
Hospital for Special Surgery, New YorkNot yet recruitingChronic Pain | Complex Regional Pain Syndrome | Causalgia | Complex Regional Pain Syndrome Type I | Complex Regional Pain Syndrome Type IIUnited States
-
State University of New York - Upstate Medical...Reflex Sympathetic Dystrophy Syndrome Association (RSDSA)RecruitingComplex Regional Pain Syndrome Type IUnited States
-
Maastricht University Medical CenterMaastricht UniversityCompleted
-
University of Vic - Central University of CataloniaInstitut Català de la SalutRecruitingComplex Regional Pain Syndrome I (CRPS I)Spain
-
Massachusetts General HospitalTerminatedComplex Regional Pain Syndrome I (CRPS I)United States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States